noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

Financial Services

Newmark Group Inc.

Newmark Arranges Sale of Golden Triangle Logistics Center in North Las[...]
Valeas Capital Partners Management LP

Suntera strengthens UK fund services proposition with acquisition of[...]
PHFA - Pennsylvania Housing[...]

11/11 PHFA Releases 2027/2028 Qualified Allocation Plan for Low-Income[...]

Economy, Business and Finance

Grove Street Advisors LLC

10/15/2026 | Press release | Archived content

Versant Ventures exits Firefly Bio to Johnson & Johnson

Firefly Bio is a biotechnology company developing the Firelink degrader antibody conjugate platform, designed to deliver targeted protein degraders directly to cancer cells to treat difficult-to-address solid tumors.

Johnson & Johnson acquired Firefly Bio for $1 billion in cash, gaining a novel technology intended to selectively target KRAS-driven cancers and other hard-to-treat malignancies while preserving healthy tissue.

GroveStreet first became a Versant Ventures LP in 2018. Read more here.

Learn more about us or reach out to schedule a meeting.

Grove Street Advisors LLC published this content on October 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 11, 2026 at 18:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format